A summary of survey results from ISPOR’s Annual North America meeting, where we gathered insights on important developments in the real world research space, including the impact of the 21st Century Cures Act on our industry.
PRA Successfully Rescues Phase II Hematology Study
A phase II single-blind, randomized, placebo-controlled trial to study the efficacy and safety of Study Drug administered as adjunctive treatment to…
Cross-Border Enrollment of Rare Disease Patients
Clinical trials in rare diseases present unique challenges unseen in trials for more common conditions. Cross-border enrollment can be key to…